Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

被引：0
作者：
Andy Göbel
Valentina M. Zinna
Stefania Dell’Endice
Nikolai Jaschke
Jan Dominik Kuhlmann
Pauline Wimberger
Tilman D. Rachner
机构：
[1] Technische Universität,Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine III
[2] German Cancer Consortium (DKTK),Institute for Research in Biomedicine (IRB Barcelona)
[3] Partner Site Dresden and German Cancer Research Center (DKFZ),Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology and Metabolism
[4] Barcelona Institute of Science and Technology,Department of Gynecology and Obstetrics
[5] Center for Healthy Aging,undefined
[6] Technische Universität Dresden,undefined
[7] Medical University of Innsbruck,undefined
[8] Medical Faculty and University Hospital Carl Gustav Carus,undefined
[9] Technische Universität Dresden,undefined
[10] National Center for Tumor Diseases (NCT),undefined
[11] Dresden,undefined
[12] Germany: German Cancer Research Center (DKFZ),undefined
[13] Heidelberg,undefined
[14] Germany; Faculty of Medicine and University Hospital Carl Gustav Carus,undefined
[15] Technische Universität Dresden,undefined
[16] Dresden,undefined
[17] Germany; Helmholtz-Zentrum Dresden - Rossendorf (HZDR),undefined
来源：
BMC Cancer | / 20卷
关键词：
Ovarian cancer; Statins; Amino-bisphosphonates; Apoptosis; Mevalonate pathway;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 508 条
[1]  
Abubaker K(2013)Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden Mol Cancer 12 24-732
[2]  
Latifi A(2012)Ovarian cancer molecular pathology Cancer Metastasis Rev 31 713-2075
[3]  
Luwor R(2013)Getting to know ovarian Cancer ascites: opportunities for targeted therapy-based translational research Front Oncol 3 256-428
[4]  
Nazaretian S(2000)Ovarian carcinoma diagnosis Cancer 89 2068-282
[5]  
Zhu H(2009)The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 415-216
[6]  
Quinn MA(2013)Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research Nat Rev Cancer 13 273-1382
[7]  
Longuespée R(2012)VEGF induces ascites in ovarian cancer patients via increasing peritoneal permeability by downregulation of Claudin 5 Gynecol Oncol 127 210-203
[8]  
Boyon C(2009)Ovarian cancer Lancet 374 1371-21
[9]  
Desmons A(2011)Recent progress in the diagnosis and treatment of ovarian cancer CA Cancer J Clin 61 183-1103
[10]  
Vinatier D(2015)Paclitaxel and its evolving role in the management of ovarian cancer Biomed Res Int 2015 1-2496
12345678910